Kenvue Inc. (NYSE:KVUE) Shares Sold by Ceredex Value Advisors LLC

Ceredex Value Advisors LLC decreased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 67.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,759,278 shares of the company's stock after selling 3,590,223 shares during the quarter. Ceredex Value Advisors LLC owned about 0.09% of Kenvue worth $37,877,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in KVUE. Citigroup Inc. purchased a new position in shares of Kenvue during the 2nd quarter worth approximately $57,000. Osaic Holdings Inc. purchased a new position in Kenvue during the second quarter valued at $144,000. Northern Trust Corp purchased a new stake in shares of Kenvue in the 2nd quarter worth about $1,244,000. PNC Financial Services Group Inc. bought a new position in Kenvue during the 2nd quarter valued at approximately $73,000. Finally, BlackRock Inc. purchased a new position in shares of Kenvue in the 2nd quarter worth about $164,895,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.4 %

Shares of KVUE stock traded up $0.08 during trading hours on Friday, reaching $20.25. 11,312,970 shares of the stock were exchanged, compared to its average volume of 16,665,205. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. Kenvue Inc. has a 12-month low of $17.82 and a 12-month high of $27.80. The company's 50-day moving average price is $20.01 and its 200-day moving average price is $20.21.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion during the quarter, compared to analysts' expectations of $3.78 billion. The company's revenue was down 2.7% on a year-over-year basis. Analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 3.95%. The ex-dividend date of this dividend was Tuesday, February 13th.

Wall Street Analyst Weigh In

Several research firms recently commented on KVUE. William Blair started coverage on Kenvue in a report on Wednesday. They issued a "market perform" rating for the company. JPMorgan Chase & Co. reduced their target price on Kenvue from $25.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 9th. The Goldman Sachs Group initiated coverage on Kenvue in a research note on Friday, March 1st. They set a "neutral" rating and a $20.00 price target for the company. UBS Group lifted their price objective on Kenvue from $20.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, December 19th. Finally, Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an "outperform" rating for the company in a research report on Friday, February 9th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $25.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.